167 related articles for article (PubMed ID: 25216718)
1. The cost of inpatient care of schizophrenia in the Polish and Ukrainian academic centers--Poznan and Lviv.
Zaprutko T; Nowakowska E; Kus K; Bilobryvka R; Rakhman L; Pogłodziński A
Acad Psychiatry; 2015 Apr; 39(2):165-73. PubMed ID: 25216718
[TBL] [Abstract][Full Text] [Related]
2. The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel.
Zaprutko T; Göder R; Kus K; Rakhman L; Bilobryvka R; Nowakowska E
Psychiatr Q; 2016 Dec; 87(4):595-603. PubMed ID: 26687383
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of inpatient care of depression in Poznan (Poland) and Kiel (Germany) in 2016.
Zaprutko T; Göder R; Kus K; Pałys W; Rybakowski F; Nowakowska E
PLoS One; 2018; 13(6):e0198890. PubMed ID: 29902259
[TBL] [Abstract][Full Text] [Related]
4. Costs of inpatient care of depression in 2014 in Polish (Poznan) and German (Kiel) hospital.
Zaprutko T; Göder R; Kus K; Pałys W; Nowakowska E
Int J Psychiatry Clin Pract; 2019 Nov; 23(4):258-264. PubMed ID: 31107117
[No Abstract] [Full Text] [Related]
5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
6. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
[TBL] [Abstract][Full Text] [Related]
7. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
Barbosa WB; Costa JO; de Lemos LLP; Gomes RM; de Oliveira HN; Ruas CM; Acurcio FA; Barbui C; Bennie M; Godman B; Guerra AA
Appl Health Econ Health Policy; 2018 Oct; 16(5):697-709. PubMed ID: 30051254
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
BMC Psychiatry; 2009 Sep; 9():54. PubMed ID: 19725969
[TBL] [Abstract][Full Text] [Related]
10. Costs of Stroke and Incidence of First Diagnosis of Atrial Fibrillation at Time of Stroke. Neurology Ward Hospital Poznań, Poland 2018.
Zaprutko T; Florczak-Wyspiańska J; Kopciuch D; Paczkowska A; Ratajczak P; Dorszewska J; Nowakowska E; Kus K
Healthcare (Basel); 2021 Aug; 9(8):. PubMed ID: 34442136
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of dental erosion among 18-year-old adolescents in the borderland districts of Lviv (Ukraine) and Lublin (Poland).
Bachanek T; Hendzel B; Wolańska E; Szybinsky V; Ogonovsky R; Hrynovets V; Samborski D; Nakonieczna-Rudnicka M; Chałas R
Ann Agric Environ Med; 2018 Mar; 25(1):66-70. PubMed ID: 29575873
[TBL] [Abstract][Full Text] [Related]
12. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
13. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
Damen J; Thuresson PO; Heeg B; Lothgren M
Appl Health Econ Health Policy; 2008; 6(4):189-97. PubMed ID: 19382819
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
[TBL] [Abstract][Full Text] [Related]
16. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
18. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
19. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
20. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
